Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 3Neoplasms 2Liver Neoplasms 2Liver Diseases 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Rheumatic Diseases 1Primary Graft Dysfunction 1Liver Failure, Acute 1Liver Failure 1Head and Neck Neoplasms 1HIV Infections 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Cisplatin 141Radiotherapy 115Cetuximab 95Docetaxel 69Radiotherapy, Intensity-Modulated 55Carboplatin 47pembrolizumab 46Surveys and Questionnaires 46Paclitaxel 41Fluorouracil 39Radiation 29Blood Specimen Collection 27Drug Therapy 26Erlotinib Hydrochloride 23Nivolumab 21Surgical Procedures, Operative 17Standard of Care 16Magnetic Resonance Spectroscopy 16Radiosurgery 14Pemetrexed 14Gemcitabine 14Everolimus 13Celecoxib 13durvalumab 12Low-Level Light Therapy 12Immunohistochemistry 12Cyclophosphamide 12Capecitabine 12Amifostine 12Chemoradiotherapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Head and Neck Neoplasms × halofantrine × Clear all
NCT00490061 2017-03-06

Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Stanford University

Phase 2 Terminated
17 enrolled 7 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡